New drug combo aims to shrink liver tumors in colorectal cancer patients

This study tests whether adding the drug ivonescimab to standard chemotherapy can shrink liver tumors in people with colorectal cancer that has spread only to the liver and cannot be surgically removed. About 40 adults will receive the combination every 3 weeks for up to 8 cycles. The goal is to see if the tumors shrink enough to allow surgery or to control the disease. Researchers will also monitor side effects.